Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Highlights from GSK Symposia at ERS 2020
INTREPID RESULTS: Investigation of Trelegy Effectiveness: Usual Practice Design.
Speaker: Professor David Halpin is Consultant Physician and Honorary Associate Professor in Respiratory Medicine at the Royal Devon and Exeter Hospital, Exeter, UK
- Treatment in the Real World
Speaker: Professor David Halpin is Consultant Physician and Honorary Associate Professor in Respiratory Medicine at the Royal Devon and Exeter Hospital, Exeter, UK.
- Improving symptoms of COPD
Speaker: Professor Francois Maltais, Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada
COPD Treatment - Symposium Recordings
- Is there a key target in COPD?
Speaker: Professor Alberto Papi, Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy
- Reducing symptoms
Speaker: Professor Claus Vogelmeier, MD, Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany.
- COPD treatment: targeting mortality
Speaker: Professor MeiLan Han, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
- Importance of preventing exacerbations
Speaker: Professor Alice M. Turner, University Hospitals Birmingham NHS Foundation Trust, and Institute of Applied Health Research, University of Birmingham, UK
Trelegy, Anoro, Relvar, Incruse, ELIPTA are registered trademark of the GlaxoSmithKline group of companies
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
